Oregon is currently home to 1216 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sleep and Metabolism
NCT05775627
Recruiting
The goal of this study is to uncover sleep and circadian mechanisms contributing to adverse metabolic health. The protocol is a 21 day (7 outpatient days, 14 inpatient days) mechanistic randomized-crossover study designed to identify the impact of chronic sleep restriction and circadian timing, independently and in combination on energy metabolism and identify the independent and combined effects on glucose tolerance.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/02/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Sleep Deprivation, Obesity, Glucose Intolerance, Weight Gain, Food Selection
Register for Updates
Circadian Time Restricted Eating
NCT05628012
Recruiting
The goal of this study is to learn more about how the time in which participants consume their meals relative to their personalized circadian rhythm influences their overall cardiometabolic health and weight. The investigators are hoping to discover if a circadian-based time restricted eating intervention will improve cardiometabolic health and decrease weight. The protocol is a 46 day prospective cohort study that includes both field and in-laboratory data collection in overweight and obese ind... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/02/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Circadian Rhythm, Cardiometabolic Health, Weight Loss, Cardiovascular Health, Time Restricted Feeding
Register for Updates
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
NCT05521022
Recruiting
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: OHSU (Oregon Health & Science University), Portland, Oregon
Conditions: Amyloidosis; Systemic
Register for Updates
Impact of Two Dietary Interventions on Simple Carbohydrate Intolerance
NCT06057376
Recruiting
In this project we want to assess impact of dietary fructose as a simple sugar intolerance on abdominal pain and compare a low FODMAP diet versus an added sugar elimination diet effectiveness on symptoms but also impact on microbiome and its metabolome.
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
04/01/2024
Locations: Oregon Health and Science University, Springfield, Oregon
Conditions: Carbohydrate Intolerance
Register for Updates
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
NCT06000423
Recruiting
This randomized double blinded trial seeks to determine whether tranexamic acid (TXA) is an efficacious treatment for contraceptive induced menstrual changes (CIMC) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (ENG implant). Participants will be randomized into the TXA treatment arm or a placebo. They will begin taking the medication after three consecutive days of bleeding. Participants will track their bleeding using an automated text mess... Read More
Gender:
FEMALE
Ages:
Between 15 years and 45 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Bleeding, Contraceptive Device; Complications
Register for Updates
Food and Circadian Timing
NCT04743271
Recruiting
The goals of this study are to uncover the influence of diet on the human circadian timing system. The protocol is a 46-day (28 outpatient days, 18 inpatient days over two 9 day visits) randomized cross-over study designed to elucidate the speed of entrainment in response to a high-fat diet.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Diet, High-Fat, Circadian Rhythm
Register for Updates
Brown Adipose Tissue Activation by Spinal Cord Stimulation
NCT04326192
Recruiting
The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Pain, Back, Obesity, Morbid, Type 2 Diabetes
Register for Updates
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
NCT02342444
Recruiting
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs. There are two standard doses of enoxaparin that are recommended by the drug companies. These two doses have never been directly compared in trauma, general, and vascular surgery patients. The purposes of this study are: 1. to compare the development of blood clots in patients receiving... Read More
Gender:
ALL
Ages:
Between 15 years and 100 years
Trial Updated:
04/01/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Register for Updates
Collaboration Oriented Approach to Controlling High Blood Pressure
NCT06124716
Recruiting
Hypertension is a significant contributor to poor cardiovascular outcomes. Self-management support tools can increase patient behaviors to improve blood pressure. The investigators created a clinical decision support app, called COACH, to integrate home blood pressure data and goals into EHR reporting and workflow with communications informed by behavioral economics principles to support shared decision-making. The study aims to measure the effectiveness of the COACH intervention in a pragmatic... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hypertension, Multiple Chronic Conditions
Register for Updates
Carrying for the Culture
NCT06148831
Recruiting
Suboptimal postpartum health outcomes in the US, including low rates of lactation and high rates of postpartum depression, contribute to high rates of perinatal mortality and morbidity as well as long-term and intergenerational health outcomes. Black birthing parents and infants are at the highest risk, with the lowest rates of lactation and the highest rates of postpartum depression. Yet most interventions to support lactation and postpartum mental health are based on models of care that are un... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Nurturely, Eugene, Oregon
Conditions: Postpartum Depression, Breast Feeding
Register for Updates
Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
NCT03813056
Recruiting
Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the t... Read More
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
03/19/2024
Locations: Devers Eye Institute, Portland, Oregon
Conditions: Fuchs Endothelial Dystrophy
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Eugene, Oregon
Conditions: Neoplasms
Register for Updates